Positive Interim Phase I Results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine

SAN DIEGO, March 29, 2024. PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials